Prasugrel Outperforms Ticagrelor in Acute Coronary Syndrome: A Real‐World Analysis
Cardiovascular Therapeutics · 2026
DOI: 10.1155/cdr/2457933 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cardiovascular Therapeutics, 2026. Verfasst von Septi Melisa und 8 weiteren Autor:innen. Beteiligte Einrichtung: International Ph.D. Program in Biotech and Healthcare Management, College of Management, Taipei Medical University, Taipei, Taiwan, tmu.edu.tw. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Prasugrel Hydrochloride. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, National Science and Technology Council.
Abstract (Originalsprache)
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is standard for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), yet real‐world comparisons of ticagrelor and prasugrel remain limited. We evaluated their relative effectiveness and safety using the TriNetX Global Collaborative Network (2010–2024). Adult ACS patients receiving prasugrel or ticagrelor within 24 h post‐PCI were included. The primary endpoint was a 1‐year composite of all‐cause mortality, myocardial infarction (MI), and cerebral infarction; secondary endpoints included individual components, major bleeding, and repeat revascularization. Propensity score matching balanced baseline characteristics, with subgroup and sensitivity analyses assessing robustness. Among 14,895 matched pairs ( n = 29,790) from 126,273 patients, prasugrel was associated with lower risk of the composite endpoint (HR 0.641; 95% CI 0.613–0.671), all‐cause mortality (HR 0.557; 95% CI 0.487–0.637), and MI (HR 0.648; 95% CI 0.616–0.680), without increased bleeding (HR 0.945; 95% CI 0.824–1.084). Repeat revascularization was higher with prasugrel (HR 1.791; 95% CI 1.639–1.957). Effects were consistent across subgroups. In this real‐world setting, prasugrel demonstrated superior effectiveness over ticagrelor in reducing mortality and ischemic events without increasing the risk of bleeding, although higher rates of repeat revascularization warrant further study. These findings support prasugrel as a potentially preferred P2Y12 inhibitor in selected ACS patients undergoing PCI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- International Ph.D. Program in Biotech and Healthcare Management, College of Management, Taipei Medical University, Taipei, Taiwan, tmu.edu.tw.
- School of Pharmacy, Taipei Medical University, Taipei, Taiwan, tmu.edu.tw.
- Faculty of Pharmacy, Sanata Dharma University, Yogyakarta, Indonesia, usd.ac.id.
- Division of Cardiology, Taipei Medical University Hospital, Taipei, Taiwan, tmuh.org.tw.
- Department of Cardiology, Chang Gung Memorial Hospital, Keelung, Taiwan, cgmh.org.tw.
- Division of Cardiovascular Medicine, Chi Mei Hospital, Tainan, Taiwan.
ORCID-Profile: Septi Melisa, Christianus Heru Setiawan, Chun-Yao Huang, Tian-Hsing Chen, Wei-Ting Chang, Wei-Pin Chang, Min-Huei Hsu, Christine Y Lu, Jason C Hsu
Förderung
- Ministry of Education
- National Science and Technology Council
Zitieren
APA
Melisa, S., Setiawan, C. H., Huang, C. Y., Chen, T. H., Chang, W. T., Chang, W. P., Hsu, M. H., Lu, C. Y., & Hsu, J. C. (2026). Prasugrel Outperforms Ticagrelor in Acute Coronary Syndrome: A Real‐World Analysis. Cardiovascular Therapeutics. https://doi.org/10.1155/cdr/2457933
Vancouver
Melisa S, Setiawan CH, Huang CY, Chen TH, Chang WT, Chang WP, et al. Prasugrel Outperforms Ticagrelor in Acute Coronary Syndrome: A Real‐World Analysis. Cardiovascular Therapeutics. 2026. doi:10.1155/cdr/2457933
BibTeX
@article{Melisa2026,
author = {Melisa, Septi and Setiawan, Christianus Heru and Huang, Chun-Yao and Chen, Tian-Hsing and Chang, Wei-Ting and Chang, Wei-Pin and Hsu, Min-Huei and Lu, Christine Y and Hsu, Jason C},
title = {Prasugrel Outperforms Ticagrelor in Acute Coronary Syndrome: A Real‐World Analysis},
journal = {Cardiovascular Therapeutics},
year = {2026},
doi = {10.1155/cdr/2457933}
}
EUVIMED